BRPI0907885A2 - Compostos antiviras hetrocíclicos - Google Patents
Compostos antiviras hetrocíclicosInfo
- Publication number
- BRPI0907885A2 BRPI0907885A2 BRPI0907885-1A BRPI0907885A BRPI0907885A2 BR PI0907885 A2 BRPI0907885 A2 BR PI0907885A2 BR PI0907885 A BRPI0907885 A BR PI0907885A BR PI0907885 A2 BRPI0907885 A2 BR PI0907885A2
- Authority
- BR
- Brazil
- Prior art keywords
- hetrocyclic
- antiviral compounds
- antiviral
- compounds
- hetrocyclic antiviral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2862908P | 2008-02-14 | 2008-02-14 | |
| US13860308P | 2008-12-18 | 2008-12-18 | |
| PCT/EP2009/051306 WO2009101022A1 (en) | 2008-02-14 | 2009-02-05 | Heterocyclic antiviral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907885A2 true BRPI0907885A2 (pt) | 2015-07-21 |
Family
ID=40521706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907885-1A BRPI0907885A2 (pt) | 2008-02-14 | 2009-02-05 | Compostos antiviras hetrocíclicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8071797B2 (pt) |
| EP (1) | EP2245023B1 (pt) |
| JP (1) | JP2011512341A (pt) |
| KR (1) | KR20100117073A (pt) |
| CN (1) | CN101910145A (pt) |
| AR (1) | AR070361A1 (pt) |
| AT (1) | ATE539070T1 (pt) |
| AU (1) | AU2009214194B2 (pt) |
| BR (1) | BRPI0907885A2 (pt) |
| CA (1) | CA2714254A1 (pt) |
| CL (1) | CL2009000305A1 (pt) |
| ES (1) | ES2377280T3 (pt) |
| IL (1) | IL204736A0 (pt) |
| MX (1) | MX2010004623A (pt) |
| PE (1) | PE20091458A1 (pt) |
| RU (1) | RU2010137635A (pt) |
| TW (1) | TW200936573A (pt) |
| WO (1) | WO2009101022A1 (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8048887B2 (en) * | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7994171B2 (en) | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8293909B2 (en) | 2008-09-11 | 2012-10-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| BR112012006628A2 (pt) * | 2009-09-24 | 2016-05-03 | Hoffmann La Roche | compostos antivírus heterocíclos |
| US8324212B2 (en) | 2010-02-25 | 2012-12-04 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8354410B2 (en) | 2010-03-11 | 2013-01-15 | Bristol-Meyers Squibb Company | Compounds for the treatment of hepatitis C |
| WO2011112191A1 (en) * | 2010-03-11 | 2011-09-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| US8324239B2 (en) * | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
| US8445497B2 (en) | 2010-06-30 | 2013-05-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| KR101594166B1 (ko) | 2010-10-26 | 2016-02-15 | 프레시디오 파마슈티칼스, 인코포레이티드 | C형 간염 바이러스의 억제제 |
| US8507683B2 (en) | 2010-12-09 | 2013-08-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| EP2744342B1 (en) | 2011-08-17 | 2019-04-24 | GlaxoSmithKline LLC | Therapeutic methods |
| PT2744332T (pt) * | 2011-08-19 | 2017-01-24 | Glaxo Group Ltd | Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| US9303020B2 (en) | 2012-02-08 | 2016-04-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| EP2831066B1 (en) | 2012-03-27 | 2016-10-05 | Bristol-Myers Squibb Company | Benzofuran derivatives for the treatment of hepatitis c |
| US9434738B2 (en) | 2013-01-10 | 2016-09-06 | Bristol-Myers Squibb Company | Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis C |
| US8962651B2 (en) | 2013-03-13 | 2015-02-24 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US9738653B2 (en) | 2013-03-14 | 2017-08-22 | Bristol-Myers Squibb Company | Fused furans for the treatment of hepatitis C |
| EP3119785B1 (en) | 2014-03-21 | 2018-08-15 | Bristol-Myers Squibb Company | Cyano containing azabenzofuran compounds for the treatment of hepatitis c |
| ES2688147T3 (es) | 2014-03-21 | 2018-10-31 | Bristol-Myers Squibb Company | Compuestos de 6H-furo[2,3-e]indol para el tratamiento de la hepatitis C |
| WO2015143256A1 (en) * | 2014-03-21 | 2015-09-24 | Bristol-Myers Squibb Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c |
| US9840511B2 (en) | 2014-05-21 | 2017-12-12 | Bristol-Meyers Squibb Company | 2-(aryl or heteroaryl-)phenyl (AZA)benzofuran compounds for the treatment of hepatitis C |
| WO2015191653A1 (en) | 2014-06-11 | 2015-12-17 | Bristol-Myers Squibb Company | Substituted 2-phenyl (aza)benzofuran compounds for the treatment of hepatitis c |
| WO2016022513A1 (en) | 2014-08-05 | 2016-02-11 | Bristol-Myers Squibb Company | Furopyridine compounds for the treatment of hepatitis c |
| WO2016045587A1 (zh) * | 2014-09-26 | 2016-03-31 | 常州寅盛药业有限公司 | 作为ns4b抑制剂的苯并呋喃类似物 |
| WO2016054299A1 (en) | 2014-10-02 | 2016-04-07 | Bristol-Myers Squibb Company | Macrocyclic benzofuran compounds for the treatment of hepatitis c |
| WO2016133972A1 (en) | 2015-02-19 | 2016-08-25 | Bristol-Myers Squibb Company | Substituted benzofuran compounds for the treatment of hepatitis c |
| US10131645B2 (en) | 2015-02-19 | 2018-11-20 | Bristol-Myers Squibb Company | Benzofurans substituted with primary benzamide as HCV inhibitors |
| WO2016133963A1 (en) | 2015-02-19 | 2016-08-25 | Bristol-Myers Squibb Company | Benzofurans substituted with secondary benzamide as hcv inhibitors |
| WO2016133948A1 (en) | 2015-02-19 | 2016-08-25 | Bristol-Myers Squibb Company | Benzofuran compounds for the treatment of hepatitis c |
| US10125137B2 (en) | 2015-02-19 | 2018-11-13 | Bristol-Myers Squibb Company | Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors |
| TWI731854B (zh) | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Ｃ型肝炎病毒聚合酶之抑制劑 |
| CN105732602B (zh) * | 2015-09-23 | 2017-04-19 | 常州寅盛药业有限公司 | 作为ns4b抑制剂的苯并呋喃类似物 |
| RS59763B1 (sr) * | 2015-11-19 | 2020-02-28 | Jiangsu hengrui medicine co ltd | Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini |
| KR102273350B1 (ko) | 2015-11-24 | 2021-07-07 | 로레알 | 모발 처리를 위한 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4537315B2 (ja) * | 2002-11-01 | 2010-09-01 | バイロファーマ・インコーポレイテッド | ベンゾフラン化合物、組成物およびｃ型肝炎感染症および関連疾患の治療または予防方法 |
| EP1981523A2 (en) * | 2006-02-09 | 2008-10-22 | Schering Corporation | Novel hcv inhibitor combinations and methods |
| WO2008100867A2 (en) * | 2007-02-12 | 2008-08-21 | Intermune, Inc. | Novel inhibitors hepatitis c virus replication |
-
2009
- 2009-02-05 AU AU2009214194A patent/AU2009214194B2/en not_active Ceased
- 2009-02-05 CN CN2009801015270A patent/CN101910145A/zh active Pending
- 2009-02-05 MX MX2010004623A patent/MX2010004623A/es active IP Right Grant
- 2009-02-05 CA CA2714254A patent/CA2714254A1/en not_active Abandoned
- 2009-02-05 EP EP09710988A patent/EP2245023B1/en not_active Not-in-force
- 2009-02-05 JP JP2010546292A patent/JP2011512341A/ja active Pending
- 2009-02-05 WO PCT/EP2009/051306 patent/WO2009101022A1/en active Application Filing
- 2009-02-05 AT AT09710988T patent/ATE539070T1/de active
- 2009-02-05 ES ES09710988T patent/ES2377280T3/es active Active
- 2009-02-05 BR BRPI0907885-1A patent/BRPI0907885A2/pt not_active IP Right Cessation
- 2009-02-05 RU RU2010137635/04A patent/RU2010137635A/ru not_active Application Discontinuation
- 2009-02-05 KR KR1020107017891A patent/KR20100117073A/ko not_active Application Discontinuation
- 2009-02-11 TW TW098104353A patent/TW200936573A/zh unknown
- 2009-02-11 CL CL2009000305A patent/CL2009000305A1/es unknown
- 2009-02-12 AR ARP090100481A patent/AR070361A1/es not_active Application Discontinuation
- 2009-02-12 US US12/378,346 patent/US8071797B2/en not_active Expired - Fee Related
- 2009-02-13 PE PE2009000213A patent/PE20091458A1/es not_active Application Discontinuation
-
2010
- 2010-03-25 IL IL204736A patent/IL204736A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL204736A0 (en) | 2010-11-30 |
| MX2010004623A (es) | 2010-06-07 |
| EP2245023A1 (en) | 2010-11-03 |
| TW200936573A (en) | 2009-09-01 |
| RU2010137635A (ru) | 2012-03-20 |
| JP2011512341A (ja) | 2011-04-21 |
| ES2377280T3 (es) | 2012-03-26 |
| US8071797B2 (en) | 2011-12-06 |
| AR070361A1 (es) | 2010-03-31 |
| ATE539070T1 (de) | 2012-01-15 |
| US20090208449A1 (en) | 2009-08-20 |
| KR20100117073A (ko) | 2010-11-02 |
| AU2009214194B2 (en) | 2012-05-17 |
| CL2009000305A1 (es) | 2010-02-19 |
| EP2245023B1 (en) | 2011-12-28 |
| PE20091458A1 (es) | 2009-09-24 |
| CN101910145A (zh) | 2010-12-08 |
| WO2009101022A1 (en) | 2009-08-20 |
| AU2009214194A1 (en) | 2009-08-20 |
| CA2714254A1 (en) | 2009-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907885A2 (pt) | Compostos antiviras hetrocíclicos | |
| SMT201600351B (it) | Composti antivirali | |
| BRPI0916233A2 (pt) | compostos heterocíclicos antivirais | |
| DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
| SMT201600045B (it) | Composti tetraciclinici c7-fluoro sostituiti | |
| BRPI0920707A2 (pt) | compostos | |
| DK2242759T3 (da) | Forbindelser | |
| DK2315696T3 (da) | Cykel | |
| DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
| BR112012005616A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0813500A2 (pt) | Compostos antivirais | |
| ATE542825T1 (de) | Substituierte piperidino-dihydrothienopyrimidine | |
| BRPI0815042A2 (pt) | Compostos de pirazol | |
| BRPI0821086A2 (pt) | Compostos inseticidas | |
| BRPI1010852A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0811264A2 (pt) | Compostos | |
| BRPI0924121A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0821349A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0907122A2 (pt) | Piridoindóis (1-azinona) substituídos | |
| DK2297162T3 (da) | Forbindelser | |
| BRPI1016266A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0814424A2 (pt) | Compostos heterociclila | |
| BRPI0916432A2 (pt) | compostos | |
| BRPI0809996A2 (pt) | Compostos | |
| DK2155273T3 (da) | Lugtregulerende genstand |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |